Skip to content
‹ Back to IndustriesHealthcare

TECHNOLOGY READINESS ASSESSMENTS AND MITIGATIONS

New product development efforts are a significant investment. Whether it is an established company that is acquiring new technology, or a startup with a new product concept hoping to move to commercialization; decisions should be made regarding what needs to be de-risked before moving to formal product development. Integrating technology readiness reviews into the product…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

New product development efforts are a significant investment. Whether it is an established company that is acquiring new technology, or a startup with a new product concept hoping to move to commercialization; decisions should be made regarding what needs to be de-risked before moving to formal product development.

Integrating technology readiness reviews into the product development process enables actionable processes that reduce project risk. This helps to avoid project delays, potential budgetary concerns, or the pressure to make design/feature compromises.

To determine whether a potential product has adequate technical maturity to effectively launch formal product development, the following steps should be considered:

  • Determine the stage of maturity of the current technology
  • Understand the implications of technology and project risks
  • Model, take measurements and analyze to decide whether core technology is capable of meeting the product requirements
  • Demonstrate that the device can provide adequate performance over the expected range of conditions
  • Determine whether the technology can scale to volume manufacturing and distribution

Evaluations begin with an objective review of each core technology critical to the operability of the device that may delay or prohibit market introduction.

This may involve proving whether core technology is adequate for use in a particular application. For example, does the new sensor being developed operate over the variety of conditions needed? Will environmental effects cause problems? Are measurements and control mechanisms adequate to provide safe and effective outcomes? Are there manufacturing difficulties in achieving the needed tolerances? These and other questions are explored, and appropriate efforts made, to bring the technology readiness level to the point that justifies moving the project to its subsequent phases.

Technology Readiness Assessment Tailored to Medical Devices

At Sunrise Labs, we implement a rigorous Technology Readiness Assessment customized specifically for medical devices. By analyzing the maturity of the technologies and the risk that each stage incurs, our assessment determines what challenges must be overcome in order for a device to be successfully engineered and commercialized.

We then improve the Technology Readiness through our feasibility Phase 0 process to prepare for a successful development effort.

To learn more about our process, check out our video on Technology Readiness.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

QinFlow's new pressure bag device skips scheduled calibration and preventive maintenance

QinFlow's new pressure bag device skips scheduled calibration and preventive maintenance

QinFlow's PressSure is a battery-powered device that holds standard pressure bags at one of three fixed preset pressures during blood or IV fluid infusions.

  • 01So far it’s manufacturer design claims; what matters next is in-service reports from early hospital or EMS adopters.

Oct 1, 2026

BedConnect’s Lindsey Joseph on matching post-acute care to patient needs

BedConnect’s Lindsey Joseph on matching post-acute care to patient needs

On I Don’t Care, BedConnect founder Lindsey Joseph and Kevin Stevenson discuss the limits of broad post-acute referrals. Their proposal is to match clinical needs, payer coverage and available beds before presenting options. CMS guidance and AHRQ discharge resources provide independent context; they do not establish BedConnect’s clinical outcomes.

  • 01BedConnect proposes matching clinical needs, payer coverage and bed availability before presenting post-acute options; this is the company’s approach, not independently validated outcome evidence.
  • 02CMS discharge-planning guidance emphasizes patient goals, treatment preferences and relevant provider quality and resource-use data.
  • 03Readmission comparisons need a defined patient group, time window and source; the interview’s roughly one-quarter/fourteen-day estimate has not been independently verified.

Sep 29, 2026

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: U.S. digital health startups raised $7.4 billion across 244 deals in H1 2026, up from $6.4 billion on 245 deals in H1 2025. The rebound is concentrated. Nineteen companies raised 20 $100 million-plus rounds that captured 45% of capital.

  • 01In H1 2026, 19 companies raised 20 mega-deals of $100 million or more, representing 45% of all capital invested, according to Rock Health.
  • 02According to Rock Health, the firm stopped labeling startups as “AI-enabled,” saying the technology is now too widespread for the label to be meaningful.

Sep 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512